Avon Donates $20 Million to NCI for Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

BETHESDA, Maryland-The Avon Products Foundation has awarded $20 million to the National Cancer Institute to help support breast cancer research and expand early-phase clinical trials of promising techniques for prevention, diagnosis, and therapy.

BETHESDA, Maryland—The Avon Products Foundation has awarded $20 million to the National Cancer Institute to help support breast cancer research and expand early-phase clinical trials of promising techniques for prevention, diagnosis, and therapy.

The foundation also awarded $10 million each to the Massachusetts General Hospital/Harvard Comprehensive Cancer Center, the University of California, San Francisco Comprehensive Cancer Center, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. It said the funds would be used at each institution to support biomedical research, clinical care for medically underserved women, and construction of new facilities focusing on breast cancer research and care.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.